111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
血清载脂蛋白 B 水平及载脂蛋白 B/载脂蛋白 A1 比值作为第二代抗精神病药物治疗患者血脂异常风险预测指标：一项回顾性队列研究
Authors Zhang JX , Huang ZQ , Yang JM, Wang WY, Li WN
Received 2 September 2025
Accepted for publication 21 November 2025
Published 8 December 2025 Volume 2025:21 Pages 2795—2804
DOI https://doi.org/10.2147/NDT.S564450
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Roger Pinder
Jia-Xuan Zhang,1 Zhi-Qiang Huang,1 Jian-Ming Yang,2 Wen-Yong Wang,3 Wei-Na Li2
1Clinical Lab, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China; 2Nanlang Outpatient Department, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China; 3Department of Geriatric Mental Disorders, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China
Correspondence: Wei-Na Li, Nanlang Outpatient Department, Zhongshan Third People’s Hospital, 80 Tianbian Main Street, Nanlang Subdistrict, Zhongshan, Guangdong, 528451, People’s Republic of China, Email liwn7@mail3.sysu.edu.cn
Purpose: To assess the predictive ability of baseline serum apolipoprotein B (ApoB) and the ratio of ApoB to apolipoprotein A1 (ApoB/ApoA1 ratio) for dyslipidemia risk in patients receiving second-generation antipsychotics (SGAs).
Patients and Methods: Medical records of patients hospitalized between March 2019 and March 2025 were retrospectively reviewed. The optimal cut-off points for baseline serum ApoB levels and the ApoB/ApoA1 ratio were identified using a maximally selected log-rank statistic analysis. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (95% CIs). The Kaplan-Meier method with Log rank testing was used to compare the cumulative incidence of dyslipidemia between groups defined by these cut-off points.
Results: Of 311 enrolled patients, 33 (10.6%) lacking baseline ApoA1 measurements were excluded from ApoB/ApoA1 ratio analyses. The optimal cut-off points were 0.70 g/L for baseline ApoB and 0.45 for the ApoB/ApoA1 ratio. Multivariable Cox proportional hazards models, fully adjusted for covariates, demonstrated significantly elevated dyslipidemia risk for patients exceeding these thresholds vs low-risk groups: adjusted HR 2.98 (95% CI: 2.05– 4.32, p < 0.001) for high ApoB and 3.17 (95% CI: 1.62– 6.22, p = 0.001) for high ApoB/ApoA1 ratio. Continuous analysis showed each 0.1 g/L ApoB increase conferred a 34% higher risk (adjusted HR 1.34, 95% CI: 1.21– 1.48, p < 0.001), while each 0.1-unit ApoB/ApoA1 ratio increase conferred a 20% higher risk (adjusted HR 1.20, 95% CI: 1.10– 1.30, p < 0.001). Kaplan-Meier curves confirmed significantly higher cumulative dyslipidemia incidence in high vs low groups for both markers (Log rank test, both p < 0.001).
Conclusion: Baseline serum ApoB levels and the ApoB/ApoA1 ratio are valuable risk markers for dyslipidemia in patients treated with SGAs.
Keywords: ApoB, ApoB/ApoA1, metabolic risk, second-generation antipsychotics, biomarker, maximally selected log-rank
1Clinical Lab, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China; 2Nanlang Outpatient Department, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China; 3Department of Geriatric Mental Disorders, Zhongshan Third People’s Hospital, Zhongshan, Guangdong, People’s Republic of China
Correspondence: Wei-Na Li, Nanlang Outpatient Department, Zhongshan Third People’s Hospital, 80 Tianbian Main Street, Nanlang Subdistrict, Zhongshan, Guangdong, 528451, People’s Republic of China, Email liwn7@mail3.sysu.edu.cn
Purpose: To assess the predictive ability of baseline serum apolipoprotein B (ApoB) and the ratio of ApoB to apolipoprotein A1 (ApoB/ApoA1 ratio) for dyslipidemia risk in patients receiving second-generation antipsychotics (SGAs).
Patients and Methods: Medical records of patients hospitalized between March 2019 and March 2025 were retrospectively reviewed. The optimal cut-off points for baseline serum ApoB levels and the ApoB/ApoA1 ratio were identified using a maximally selected log-rank statistic analysis. Multivariable Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (95% CIs). The Kaplan-Meier method with Log rank testing was used to compare the cumulative incidence of dyslipidemia between groups defined by these cut-off points.
Results: Of 311 enrolled patients, 33 (10.6%) lacking baseline ApoA1 measurements were excluded from ApoB/ApoA1 ratio analyses. The optimal cut-off points were 0.70 g/L for baseline ApoB and 0.45 for the ApoB/ApoA1 ratio. Multivariable Cox proportional hazards models, fully adjusted for covariates, demonstrated significantly elevated dyslipidemia risk for patients exceeding these thresholds vs low-risk groups: adjusted HR 2.98 (95% CI: 2.05– 4.32, p < 0.001) for high ApoB and 3.17 (95% CI: 1.62– 6.22, p = 0.001) for high ApoB/ApoA1 ratio. Continuous analysis showed each 0.1 g/L ApoB increase conferred a 34% higher risk (adjusted HR 1.34, 95% CI: 1.21– 1.48, p < 0.001), while each 0.1-unit ApoB/ApoA1 ratio increase conferred a 20% higher risk (adjusted HR 1.20, 95% CI: 1.10– 1.30, p < 0.001). Kaplan-Meier curves confirmed significantly higher cumulative dyslipidemia incidence in high vs low groups for both markers (Log rank test, both p < 0.001).
Conclusion: Baseline serum ApoB levels and the ApoB/ApoA1 ratio are valuable risk markers for dyslipidemia in patients treated with SGAs.
Keywords: ApoB, ApoB/ApoA1, metabolic risk, second-generation antipsychotics, biomarker, maximally selected log-rank